Kaleido Biosciences Raises $65M in Funding

Kaleido Biosciences, a Bedford, Mass.-based clinical-stage biotechnology company, completed an additional capital raise, for a total of $65m in funds raised to date.

The funding will be used to further advance discovery and testing of Kaleido’s novel chemistries.

Led by biopharmaceutical veteran Mike Bonney, chief executive officer and board chair, Kaleido has built an R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship VentureLabs, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data.
The company is also creating consumer products that optimize the microbiome’s natural roles in promoting health.

The round was led by founding investor, Flagship Pioneering, and included participation from a number of institutional and individual healthcare investors, including Bonney.

At Kaleido, Bonney is joined by a management team, including:
– Geoffrey von Maltzahn, co-founder and president of Kaleido and partner at Flagship Pioneering;
– Jared Silverman, senior vice president of research;
– Ruth Thieroff-Ekerdt, chief medical officer;
– Jeffery Moore, senior vice president of finance & operations;
– Jeremy Buzzard, senior vice president, corporate;
– Michele Fite, president, food and nutrition division; and
– Rob Miller, chief scientific officer, food and nutrition division.

As Board Chair at Kaleido, Bonney is joined by:
– Noubar Afeyan, CEO of Flagship Pioneering and co-founder of Kaleido;
– Geoffrey von Maltzahn, co-founder and president of Kaleido and partner at Flagship Pioneering;
– Brian Baynes, founding board member of Kaleido and venture partner at Flagship Pioneering;
– Anthony Quinn, former head of R&D at Synageva;
– Ronald Kahn, former president of the Joslin Diabetes Center and winner of the Wolf Prize in Medicine;
– Peter Barton Hutt, former chief counsel to the FDA;
– Robert Connelly, CEO of Axcella Health; and
– Jonathan McIntyre, senior vice president, PepsiCo Research & Development.



Join the discussion